C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients

PURPOSE: Overall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum C-reactive protein (CRP) in non-small cell lung cancer (NSCLC) trials with atezolizumab (anti-PD-L1) as an early OS surrogate. METHODS: S...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Namrata S., Zou, Wei, Mocci, Simonetta, Sandler, Alan, Ballinger, Marcus, Flynn, Susan, Kowanetz, Marcin, Hegde, Priti S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857603/
https://www.ncbi.nlm.nih.gov/pubmed/33534859
http://dx.doi.org/10.1371/journal.pone.0246486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857603/
https://www.ncbi.nlm.nih.gov/pubmed/33534859
http://dx.doi.org/10.1371/journal.pone.0246486

Ejemplares similares